Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up on Strong Earnings

Key Points

• Neurocrine posted strong quarterly results: Adjusted EPS was $3.29 versus the $1.91 consensus, while revenue rose 41.3% year over year to $1.12 billion, exceeding expectations.
• Commercial momentum strengthened: Quarterly product sales surpassed $1 billion for the first time, and the company raised its 2026 INGREZZA sales guidance to $2.9 billion–$2.925 billion.
• Shares surged and analysts turned more bullish: NBIX opened at $159 after closing at $145.35, while several firms raised price targets; the stock carries a “Moderate Buy” consensus rating and a $201.45 average target.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $145.35, but opened at $159.00. Neurocrine Biosciences shares last traded at $165.2390, with a volume of 749,745 shares traded.

The company reported $3.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $1.38. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the company posted $2.04 EPS. The business's revenue was up 41.3% on a year-over-year basis.

Neurocrine Biosciences News Summary

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong third-quarter performance: Neurocrine reported adjusted earnings of $3.29 per share, well above estimates ranging from $1.91 to $2.67 and up from $2.04 a year earlier. Revenue rose 41.3% year over year to $1.12 billion, exceeding the approximately $1.04 billion consensus. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Product sales surpassed $1 billion: Management said quarterly net product sales exceeded $1 billion for the first time, reflecting strong demand across its portfolio. The company also raised 2026 net sales guidance for INGREZZA to $2.9 billion-$2.925 billion, reinforcing expectations for continued commercial momentum. Neurocrine Biosciences Crosses $1 Billion in Quarterly Product Sales
• Positive Sentiment: Analysts raised targets: Canaccord Genuity increased its target from $210 to $220 and assigned a “buy” rating, while Piper Sandler raised its target from $210 to $215 and maintained an “overweight” rating. Both targets imply substantial appreciation from the referenced $145.35 share price. Canaccord Genuity Group Recommendations Piper Sandler Recommendations
• Neutral Sentiment: Investor focus is likely to remain on management’s earnings-call commentary regarding demand trends, guidance and the company’s broader product pipeline. No material negative development was reported in the supplied coverage. Neurocrine Q3 2026 Earnings Call Transcript

Analyst Ratings Changes

A number of equities analysts have issued reports on NBIX shares. Truist Financial lifted their target price on shares of Neurocrine Biosciences from $200.00 to $213.00 and gave the stock a "buy" rating in a research report on Monday, August 3rd. Canaccord Genuity Group increased their price target on shares of Neurocrine Biosciences from $210.00 to $220.00 and gave the company a "buy" rating in a research report on Tuesday. Needham & Company LLC reissued a "buy" rating and set a $204.00 price objective on shares of Neurocrine Biosciences in a research note on Friday, October 16th. Royal Bank Of Canada raised their price objective on shares of Neurocrine Biosciences from $187.00 to $190.00 and gave the stock an "outperform" rating in a research note on Tuesday. Finally, Wall Street Zen downgraded Neurocrine Biosciences from a "buy" rating to a "hold" rating in a research report on Sunday, August 9th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Neurocrine Biosciences has an average rating of "Moderate Buy" and a consensus price target of $201.45.

Insider Activity

In related news, CFO Matt Abernethy sold 2,311 shares of the business's stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $157.20, for a total value of $363,289.20. Following the completion of the transaction, the chief financial officer owned 42,808 shares of the company's stock, valued at approximately $6,729,417.60. The trade was a 5.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider David Boyer sold 826 shares of the company's stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $157.45, for a total transaction of $130,053.70. Following the completion of the transaction, the insider owned 8,722 shares in the company, valued at approximately $1,373,278.90. This trade represents a 8.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 4.60% of the company's stock.

Hedge Funds Weigh In On Neurocrine Biosciences

Institutional investors have recently modified their holdings of the company. Basecamp Wealth Advisors LLC boosted its position in Neurocrine Biosciences by 582.9% during the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company's stock worth $31,000 after acquiring an additional 204 shares during the last quarter. Raleigh Capital Management Inc. raised its holdings in Neurocrine Biosciences by 561.8% in the 3rd quarter. Raleigh Capital Management Inc. now owns 225 shares of the company's stock valued at $32,000 after acquiring an additional 191 shares during the last quarter. Cassaday & Co Wealth Management LLC acquired a new position in Neurocrine Biosciences in the 1st quarter valued at $33,000. Ascentis Independent Advisors purchased a new position in shares of Neurocrine Biosciences during the 1st quarter worth $40,000. Finally, TrinityBridge Ltd purchased a new position in shares of Neurocrine Biosciences during the 2nd quarter worth $45,000. Institutional investors and hedge funds own 92.59% of the company's stock.

Neurocrine Biosciences Stock Up 14.5%

The firm has a fifty day moving average price of $146.49 and a 200-day moving average price of $147.45. The firm has a market cap of $16.91 billion, a price-to-earnings ratio of 24.36, a PEG ratio of 0.64 and a beta of 0.36.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company's research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine's leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.